Orlando, Florida — December 8, 2025 — SeekIn Inc. announced that three clinical studies featuring its proprietary technologies LeukoPrint and MSNPseq are being presented at the 67th American Society of Hematology (ASH) Annual Meeting.
Overview of ASH Presentations
At the 2025 ASH Annual Meeting, three clinical studies led by SeekIn and its collaborators will showcase new data on copy number aberration (CNA) detection in acute myeloid leukemia (AML) and multiple myeloma (MM), as well as ultra–high-sensitivity chimerism monitoring after allogeneic hematopoietic stem cell transplantation. The results highlight the potential of LeukoPrint, a shallow whole-genome sequencing (sWGS) assay, and MSNPseq, a multiple single nucleotide polymorphism sequencing assay, to reshape precision diagnosis, risk stratification, and minimal residual disease (MRD) monitoring in hematologic malignancies.
AML Study with LeukoPrint
The first poster, titled “Interim Results of a Multi-Center Clinical Trial Evaluating Copy Number Aberrations via Shallow Whole-Genome Sequencing (LeukoPrint) in Acute Myeloid Leukemia,” reports interim data from 205 prospective collected AML patients across 13 centers (Trial ID ChiCTR2300077695). This multi-center prospective study showed that LeukoPrint detected CNAs in 42.4% of patients, yielding a 24.9% improvement in CNA positivity compared with conventional karyotyping, and reclassified 35 patients with normal or failed karyotypes by identifying clinically relevant CNAs, including upgrades to European LeukemiaNet (ELN) high-risk status.
Dynamic sWGS monitoring showed that persistent CNA positivity after induction therapy was associated with lack of treatment response, whereas 95.5% of patients achieving complete remission demonstrated CNA clearance, supporting the use of LeukoPrint for molecular response assessment. The study also found copy-neutral loss of heterozygosity (CN-LOH) in 12.2% of patients, providing additional prognostic information beyond standard cytogenetic testing.
Multiple Myeloma Study with LeukoPrint
The second poster, “Interim results from a multicenter trial assessing the clinical relevance of copy number aberrations detected by a shallow whole-genome sequencing analysis (LeukoPrint) in multiple myeloma,” is also a multi-center prospective study including 102 newly diagnosed, active MM patients from seven centers (Trial ID ChiCTR2300077768). LeukoPrint identified CNAs in 89.2% of MM cases, while conventional karyotyping showed abnormalities in only 8.8% of patients, underscoring the superior sensitivity of genome-wide sWGS.
In a head-to-head comparison with fluorescence in situ hybridization (FISH) targeting 1q gain, 13q deletion, and 17p13 deletion, overall concordance was 88%, and LeukoPrint detected CNAs in 80.0% of FISH-negative patients. Matched bone marrow and plasma circulating tumor DNA (ctDNA) samples demonstrated CNA detection rates of 89.1% and 61.4%, respectively, supporting the feasibility of LeukoPrint-based liquid biopsy for MM genomic profiling and disease monitoring.
Transplant Chimerism Study with MSNPseq
The third poster, “Enhanced Chimerism Detection with Multiple Single Nucleotide Polymorphism Sequencing: Improving Risk Stratification Post-Allogeneic Hematopoietic Stem Cell Transplantation,” presents data from 741 transplant recipients monitored at three sequential time points (+30, +60, and +90 days). Using MSNPseq, the lower limit of chimerism detection was improved from approximately 1–5% with short tandem repeat (STR) assays to 0.01%, enabling much earlier identification of emerging recipient cells.
The study defines “microchimerism” (mCHIM, 99% to <100% donor) and “subthreshold chimerism” (sCHIM, 95% to <100% donor) and shows that patients in these categories have significantly poorer progression-free and overall survival compared with those with complete donor chimerism (cCHIM). These findings support MSNPseq as a next-generation standard for post-transplant chimerism monitoring, enabling earlier relapse warning and more individualized intervention strategies.
Future Directions
Across AML, MM, and post-transplant settings, the three ASH presentations demonstrate that LeukoPrint and MSNPseq can overcome key limitations of karyotyping, FISH, and STR assays by offering higher sensitivity, broader genomic coverage, and dynamic monitoring capability. SeekIn plans to further validate these technologies in these ongoing prospective multicenter trials and to work with clinical partners to integrate them into routine hematology practice to improve risk stratification, response evaluation, and long-term patient outcomes.